Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01284309 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects
A Phase 1 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 321
- Enrollment target
NCT01284309 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 321 participants.
The verdict
NCT01284309, a Phase 1 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 321 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the affect of mirabegron on intraocular pressure (IOP) in healthy subjects.
Interventions
- DRUG Placebo
- DRUG Mirabegron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 321 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01284309
The ClinicalTrials.gov registry entry for NCT01284309 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 321 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01284309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01284309 about?
NCT01284309 is a clinical study titled "A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects". The purpose of this study is to assess the affect of mirabegron on intraocular pressure (IOP) in healthy subjects.
What is the current status of trial NCT01284309?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 321 participants. The study started on 2010-11. Estimated completion is 2011-02.
What interventions are being tested in trial NCT01284309?
The interventions under investigation include: Placebo (DRUG), Mirabegron (DRUG).
Who is sponsoring clinical trial NCT01284309?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.